<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545463</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC-1534</org_study_id>
    <nct_id>NCT04545463</nct_id>
  </id_info>
  <brief_title>Hypocholesterolemic Effect of Fibracep</brief_title>
  <acronym>FIBRACEP</acronym>
  <official_title>Validation Study of the Effects of FIBRACEP Supplementation on the Lipid Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitat de Lleida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitat de Lleida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIBRACEP is an onion based fiber that has demonstrated in vitro and in animal models the&#xD;
      capacity to increase HDL cholesterol levels as well to improve other lipid profile species.&#xD;
      This intervention aims to demonstrate FIBRACEP's blood lipid profile improvement effect. For&#xD;
      that purpose, hypercholesterolemic subjects will be recruited and given a daily dose of 7 g&#xD;
      of FIBRACEP for two months. Changes in blood lipid profile will be the end-point of the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">May 1, 2016</completion_date>
  <primary_completion_date type="Actual">May 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood HDL-cholesterol</measure>
    <time_frame>2 months</time_frame>
    <description>Cholesterol content in HDL lipoproteins determined by nuclear magnetic resonance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipid profile</measure>
    <time_frame>2 months</time_frame>
    <description>Cholesterol content in LDL, VLDL (Very low-density lipoproteins) density and IDL lipoproteins determined by NMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipoprotein number</measure>
    <time_frame>2 months</time_frame>
    <description>Number of lipoproteins determined by nuclear magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipoprotein size</measure>
    <time_frame>2 months</time_frame>
    <description>The average size of each lipoprotein specie (HDL, LDL, VLDL, IDL) determined by nuclear magnetic resonance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Insoluble Fibre</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cookies with insoluble fibre (wheat bran)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soluble Fibre</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cookies with soluble fibre (Psyllium plantago)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FIBRACEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cookies with FIBRACEP</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FIBRACEP</intervention_name>
    <description>A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months</description>
    <arm_group_label>FIBRACEP</arm_group_label>
    <other_name>Onion fiber</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>INSOLUBLE</intervention_name>
    <description>A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months</description>
    <arm_group_label>Insoluble Fibre</arm_group_label>
    <other_name>Insoluble fibre from wheat bran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SOLUBLE</intervention_name>
    <description>A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months</description>
    <arm_group_label>Soluble Fibre</arm_group_label>
    <other_name>Soluble fibre from Psyllium plantago</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Total cholesterol levels above 200 mg/dL, observed in at least 3 different days&#xD;
&#xD;
          -  Body mass index between 25 and 35 (Overweight and obesity type 1 diagnosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 and Type 2 Diabetes&#xD;
&#xD;
          -  Allergy to any compound described in FIBRACEP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>José Serrano Casasola</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitat de Lleida</investigator_affiliation>
    <investigator_full_name>José Serrano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fiber</keyword>
  <keyword>Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>By request to Principal Investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>January 2021, for 2 years.</ipd_time_frame>
    <ipd_access_criteria>By e-mail to Principal Investigator, who will decide to share the data if fulfill research purposes.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

